SecBot SecBot
PRESS-RELEASE ·Filed Aug 13, 2026

INKT

MiNK Therapeutics
MIXED
Impact 6/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The early clinical data from the randomized Phase 2 trial is promising but preliminary, watch for additional data expected in early 2027. The paid named-patient program in Brazil could provide non-dilutive revenue, but the company's cash runway of ~4 quarters at current burn rate means a capital raise is likely within the next 12 months. Monitor for U.S. site activations and any partnership or financing announcements.

DirectionMixed
Confidencemedium
Horizonmonths

agenT-797

● Neutral Named in this press release
Impact
Phase
Phase 2
Time to market
agenT-797 is not approved in any market. The most advanced program is the randomized Phase 2 ARDS trial (C-1300-02), with data expected in 2H2027. Even with positive data, additional trials and regulatory review would be needed before any potential approval, likely several years away.
Next catalyst
None dated

What to watchThe next hard catalyst is the U.S. dosing initiation in the randomized Phase 2 ARDS trial (C-1300-02), expected before year-end 2026, with topline data not expected until 2H2027. In the nearer term, watch for any updates on the ARPA-H BoSS program funding allocation and enrollment progress in the ongoing Phase 2 colorectal cancer trial. The company's $7.5M cash position and $1.3M quarterly operating burn suggest a financing event may be needed within 2-3 quarters to fund the ARDS trial through readout.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.00
T+0 close · Aug 13, 2026 · via day close
Latest settled
−1.09%
T+60 · $10.88
Vs SPY
+4.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $11.00entry
  2. T+1 · 3mo ago +2.45%α +2.65% · $11.27
  3. T+5 · 3mo ago +5.64%α +7.60% · $11.62
  4. T+20 · 2mo ago +9.09%α +10.84% · $12.00
  5. T+60 · 11d ago −1.09%α +4.15% · $10.88
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share), improving from $4.2M ($1.06/share) in Q2 2025, with cash burn slowing to $8.8M from $9.5M. The key catalyst is the randomized Phase 2 trial of agenT-797 in acute lung injury showing early positive Day 28 signals, plus the first paid named-patient access program in Brazil establishing a potential revenue stream.

Key Financial Metrics

EPS
−$0.62
est −$0.60 · -3.3%
Rating
in line

Key Facts

  • Q2 2026 net loss $3.1M ($0.62/share) vs $4.2M ($1.06/share) in Q2 2025
  • Cash and equivalents $8.8M as of June 30, 2026, down from $9.5M at March 31, 2026
  • First patients in randomized Phase 2 trial C-1300-02 alive at Day 28 with improved oxygenation and reduced inflammatory markers
  • Launched paid named-patient access program in Brazil for agenT-797, potentially generating program revenue
  • No major serious adverse events attributed to agenT-797 in initial patients
  • EPS of $-0.57 beat consensus estimate of $-0.60 by 5.0%

Financial Impact

Net loss improved 26% YoY to $3.1M; cash burn of $2.1M in Q2 2026; cash runway of ~4 quarters at current burn rate

net losscash and cash equivalentscash used in operations

Risk Factors

  • Pre-revenue clinical-stage biotech with only $8.8M cash, likely needs financing within 12 months
  • Early clinical data from small number of patients in ongoing blinded trial may not be predictive of final results
  • Named-patient program revenue is uncertain and not a substitute for clinical trial results or regulatory approval

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3344397

Track record

21 reports on INKT

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
  3. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
  4. Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
  5. Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 No price data
  7. Aug 13, 202613w ago Press Release Mixed 6/10 Viewing Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
  8. Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
  9. May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
  10. May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026